1-8 of 8
Samira Syed
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P2-11-11: Clinicopathological features predictive of neoadjuvant immune checkpoint inhibitor benefit in triple-negative breast cancer

Free
Shipra Gandhi, Gary Tozbikian, Oluwole Fadare, Samira Syed, Briana To, Dionisia Quiroga, Song Yao, Kristopher Attwood, Yisheng Fang, Thaer Khoury
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P2-11-11.
https://doi.org/10.1158/1557-3265.SABCS24-P2-11-11
Published: 13 June 2025
View articletitled, Abstract P2-11-11: Clinicopathological features predictive of neoadjuvant immune checkpoint inhibitor benefit in triple-negative breast cancer
Journal Articles

Abstract RF3-05: A Phase 2 Study of Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP)

Free
Heather McArthur, Isaac Chan, Jorge Leal, Stephanie Rice, Laura Spring, Katherine Sanchez, Jin Sun Bitar, Nisha Unni, Samira Syed, Reva Basho, Alison Conlin, Sasha Stanton, Kelly Perlewitz, Glenda Delgado, Namrata Peswani, Yuan Yuan, David Chan, Ina Patel, Swati Sikaria, Navid Sadeghi, Mai Badran, Lynette Currie, Jessica Curtin, Natalie Boy, Joey Di Padova, Christina DiLauro Abaya, Michelle Phillips, Nasir Qureshi, Meredith Carter, Stephen Shiao, Farnaz Dadmanesh, Rochelle Horadam, Ravi Thadhani, Sujata Patil, Adam Brufsky, David Page
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): RF3-05.
https://doi.org/10.1158/1557-3265.SABCS24-RF3-05
Published: 13 June 2025
View articletitled, Abstract RF3-05: A Phase 2 Study of Neoadjuvant HER2-targeted Therapy +/- Immunotherapy with Pembrolizumab (neoHIP)
Journal Articles

Abstract P3-12-30: Phase I trial of pegylated liposomal doxorubicin chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic HER2 negative breast cancer

Free
Sangeetha Reddy, Cesar Santa-Maria, Virginia Kaklamani, Joyce O’Shaughnessy, Nisha Unni, Navid Sadeghi, Samira Syed, Joshua Gruber, Yisheng Fang, Isaac Chan, Namrata Peswani, Shahbano Shakeel, Meredith Carter, Kelly Kyle, Dawn Klemow, Nan Chen, Rita Nanda, Heather McArthur, Suzanne Conzen, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P3-12-30.
https://doi.org/10.1158/1557-3265.SABCS24-P3-12-30
Published: 13 June 2025
View articletitled, Abstract P3-12-30: Phase I trial of pegylated liposomal doxorubicin chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic HER2 negative breast cancer
Journal Articles

Abstract PS1-01: Tumor Infiltrating Lymphocytes (TILs) as a Predictive Marker of Pathological Complete Response (pCR) in a Diverse Patient Population with Early Triple Negative Breast Cancer (TNBC) Treated with the Neoadjuvant KEYNOTE-522 Regimen

Free
Riya Albert, Joshua Thomas, Navid Sadeghi, Sangeetha Reddy, Glenda Delgado, Heather McArthur, Samira Syed, Deborah Farr, Nisha Unni
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): PS1-01.
https://doi.org/10.1158/1557-3265.SABCS24-PS1-01
Published: 13 June 2025
View articletitled, Abstract PS1-01: Tumor Infiltrating Lymphocytes (TILs) as a Predictive Marker of Pathological Complete Response (pCR) in a Diverse Patient Population with Early Triple Negative Breast Cancer (TNBC) Treated with the Neoadjuvant KEYNOTE-522 Regimen
Journal Articles

Abstract P1-08-17: Successful Treatment of Early Triple-Negative Breast Cancer with Chemotherapy and Immune Checkpoint Inhibitor in the Setting of Sickle Cell Disease: a Case Report

Free
Stevany Saxon-Filipe, Luise Froessl, Samira Syed
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P1-08-17.
https://doi.org/10.1158/1557-3265.SABCS24-P1-08-17
Published: 13 June 2025
View articletitled, Abstract P1-08-17: Successful Treatment of Early Triple-Negative Breast Cancer with Chemotherapy and Immune Checkpoint Inhibitor in the Setting of Sickle Cell Disease: a Case Report
Journal Articles

Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors

Free
Alejandro D. Ricart, Jordan D. Berlin, Kyriakos P. Papadopoulos, Samira Syed, Daniel W. Drolet, Charlotte Quaratino-Baker, Julie Horan, Jon Chick, Wendy Vermeulen, Anthony W. Tolcher, Eric K. Rowinsky, Mace L. Rothenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7947–7955.
https://doi.org/10.1158/1078-0432.CCR-08-0864
Published: 01 December 2008
View articletitled, Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors
Open the PDF for Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors in another window
Journal Articles

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

Free
Alain C. Mita, Lisa A. Hammond, Peter L. Bonate, Geoffrey Weiss, Heather McCreery, Samira Syed, Mitchell Garrison, Quincy S.C. Chu, Johann S. DeBono, Christopher B. Jones, Steve Weitman, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5207–5215.
https://doi.org/10.1158/1078-0432.CCR-06-0179
Published: 01 September 2006
View articletitled, Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties

Free
Samira Syed, Chris Takimoto, Manuel Hidalgo, Jinee Rizzo, John G. Kuhn, Lisa A. Hammond, Garry Schwartz, Anthony Tolcher, Amita Patnaik, S. Gail Eckhardt, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (19): 6512–6521.
https://doi.org/10.1158/1078-0432.CCR-04-0804
Published: 08 October 2004
View articletitled, A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties
Open the PDF for A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties in another window